0.69012.66% ( -0.100 )
Delay Closed: Nov 20, 16:08:00Valuation
Current ValuationThe current P/E ratio is -190.81, below the reasonable range, cheaper than 95.48% of the time in the past 5 years, and the industry ranks 52/54, the industry Median 7.34.
-190.81xP/E
HK$0.69Stock price
HK$-0.00Earnings per share
-190.81xP/E
Stock priceHK$0.69Earnings per shareHK$-0.00
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -18.36x
- Typical range
- -59.50x–-2.81x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 7.34x
09182736
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 7.34x
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
06887HKSUNSHINE PHARMA | -63.55x | -- | HK$20.85B |
02630HKVIGONVITA-B | -34.47x | -- | HK$12.10B |
09637HKALEBUND-B | -8.71x | 48.51% | HK$7.06B |
00570HKTRAD CHI MED | -4.70x | 223.71% | HK$5.46B |
02575HKXUANZHUBIO-B | -16.06x | -- | HK$3.88B |
01477HKOCUMENSION-B | -25.70x | 52.42% | HK$3.71B |
09941HKSINOTAUPHARMA-B | -- | -- | HK$3.41B |
02552HKHUA MEDICINE-B | -17.16x | 104.78% | HK$2.13B |
01349HKFUDANZHANGJIANG | -17.69x | -- | HK$2.12B |
02652HKCF PHARMTECH | -232.95x | -- | HK$1.82B |
06622HKZHAOKE OPHTH-B | -4.06x | -- | HK$1.00B |
01652HKFUSEN PHARM | -190.81x | -- | HK$510.12M |
01011HKNT PHARMA | -14.15x | -- | HK$449.14M |
01643HKMODERN CHI MED | -5.60x | -- | HK$270.00M |
08329HKNEP INTERLONG | -3.20x | -- | HK$194.65M |
00575HKREGENT PACIFIC | -12.30x | -- | HK$188.22M |
00858HKEXTRAWELL PHAR | -0.17x | -- | HK$168.20M |
01312HKKONTA CHINA | -0.79x | -- | HK$167.66M |
00455HKTIANDA PHARMA | -2.15x | -- | HK$148.35M |
01498HKPURAPHARM | -4.55x | -- | HK$125.94M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
